Mn(III) mixed-ligand complexes with bis-pyrazolones and ciprofloxacin drug: synthesis, characterization and antibacterial activities

2011 ◽  
Vol 25 (6) ◽  
pp. 429-436 ◽  
Author(s):  
C.K. Modi ◽  
D.H. Jani
2020 ◽  
Vol 10 (03) ◽  
pp. 67-85
Author(s):  
Temitayo O. Aiyelabola ◽  
Iyanuoluwa E. Okunade ◽  
Johan H. L. Jordaan ◽  
Daniel P. Otto

2021 ◽  
Vol 12 (2) ◽  
pp. 1962-1973

Antibiotic resistance of pathogens to the current commercially available drugs is a serious problem. To curve this problem, the discovery of active compounds with a new mode of action is insistent. In line with this, we report two new complexes; mononuclear [Co(L1)2(L2)(H2O)]Cl2 and binuclear [Co2(L1)4(L2)(H2O)2]Cl4 using precursor complex, [Co(L1)2(H2O)2]Cl2, synthesized before; where L1: 2,2’-bipyridine and L2: ethylenediamine. The precursor complex was prepared from CoCl2.6H2O and L1 in ethanol, treated with a different mole of L2 under optimized reaction conditions to give the corresponding mono-and binuclear cobalt(II) mixed ligand complexes. These complexes were characterized using the spectroscopic technique (ICP-OES, UV-Vis, FT-IR) and physicochemical methods (chloride determination, thermal analysis, and conductance measurement). Their antibacterial activities were also tested against two Gram-negative (Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae)) and two Gram-positive (Staphylococcus aureus (S. aureus), Streptococcus pyogenes (S. pyogenes)) bacteria using the disc diffusion method. The new complexes showed better activities against K. pneumoniae than the reference Gentamycin. Furthermore, [Co(L1)2(L2)(H2O)]Cl2 demonstrated better activity than Gentamycin against S. aureus and E. coli.


Author(s):  
Tahmeena Khan ◽  
Rumana Ahmad ◽  
Iqbal Azad ◽  
Saman Raza ◽  
Seema Joshi ◽  
...  

Background: Mixed ligand-metal complexes are efficient chelating agents because of flexible donor ability. Mixed ligand complexes containing hetero atoms sulphur, nitrogen and oxygen have been probed for their biological significance. Objective: Nine mixed ligand-metal complexes of 2-(butan-2-ylidene) hydrazinecarbothioamide (2-butanone thiosemicarbazone) and pyridine, bipyridine or 2-picoline as co-ligands were synthesized with Cu, Fe and Zn. The complexes were tested against MDA-MB231 (MDA) and A549 cell lines. Antibacterial activity was tested against S. aureus and E. coli. The drug character of the complexes was evaluated on several parameters viz. physicochemical properties, bioactivity scores, toxicity assessment and absorption, distribution, metabolism, excretion and toxicity (ADMET) profile assessment using various automated softwares. Molecular docking of the complexes was also performed with two target proteins. Method and Results: The mixed ligand-metal complexes were synthesized by condensation reaction for 4-5 h. The characterization was done by elemental analysis, 1H-NMR, FT-IR, molar conductance and UV spectroscopies. Molecular docking was performed against ribonucleotide reductase (RR) and topoisomerase II (topo II). [Cu(C5H11N3S)(py)2(CH3COO)2], [Zn(C5H11N3S)(bpy)(SO4)] and [Zn(C5H11N3S)(2-pic)2(SO4)] displayed the lowest binding energies with respect to RR. Against topo II [Cu(C5H11N3S)(py)2(CH3COO)2], [Cu(C5H11N3S)(bpy)(CH3COO)2] and [Zn(C5H11N3S)(2-pic)2(SO4)] had the lowest energies. The druglikness assessment was done using Leadlikeness and Lipinski’s rules. Against topo II [Cu(C5H11N3S)(py)2(CH3COO)2], [Cu(C5H11N3S)(bpy)(CH3COO)2] and [Zn(C5H11N3S)(2-pic)2(SO4)] had the lowest energies. Not more than two violations were obtained in case of each filtering rule showing drug like character of the mixed ligand complexes. Several of the complexes exhibited positive bioactivity scores and almost all the complexes were predicted to be safe with no hazardous effects. All the complexes were predicted to have no mutagenic character as shown by the Ames test [Zn(C5H11N3S)(py)2(SO4)] showed potential activity against MDA. [Co(C5H11N3S(bpy)(Cl)2] was also active against MDA. [Cu(C5H11N3S)(2-pic)2(CH3COO)2] also showed 27.6% cell viability at 100 µM against MDA. Against A549 [Co(C5H11N3S)(py)2(Cl)2], [Cu(C5H11N3S)(py)2(CH3COO)2] and [Co(C5H11N3S(bpy)(Cl)2] were active. [Co(C5H11N3S)(bpy)(Cl)2] and [Cu(C5H11N3S)(2-pic)2(CH3COO)2] were active against S. aureus. [Co(C5H11N3S)(2-pic)2(Cl)2] and [Zn(C5H11N3S)(2-pic)2(SO4)] were active at lower concentrations against S.aureus. Against E. coli, [Zn(C5H11N3S)(2-pic)2(SO4)] showed activity at 18-20mg dose range.


1985 ◽  
Vol 50 (6) ◽  
pp. 1383-1390
Author(s):  
Aref A. M. Aly ◽  
Ahmed A. Mohamed ◽  
Mahmoud A. Mousa ◽  
Mohamed El-Shabasy

The synthesis of the following mixed ligand complexes is reported: [Ni(phdtc)2(dpm)2], [Ni(phdtc)2(dpe)2], [Ni(phdtc)2(dpp)3], [Ni(1-naphdtc)2(dpm)2], [Ni(1-naphdtc)2], and [Ni(1-naphdtc)2(dpp)2], where phdtc = PhNHCSS-, 1-naphdtc = 1-NaPhNHCSS-, dpm = Ph2PCH2PPh2, dpe = Ph2P(CH2)2PPh2, and dpp = Ph2P(CH2)3PPh2. The complexes are characterised by microanalysis, IR and UV-Vis spectra, magnetic measurements, conductivity, X-ray powder diffraction, and thermal analysis. All the mixed ligand complexes are diamagnetic, and thus a square-planar or square-pyramidal (low-spin) structure was proposed for the present complexes.


Sign in / Sign up

Export Citation Format

Share Document